Protalix BioTherapeutics, Inc.
Elfabrio
Fabry disease
Resolved
111days ago
Approval decision · Mar 18, 2026
What's at stake
A final FDA approval decision on Elfabrio for Fabry disease is expected Mar 18, 2026.
Primary source
· SEC 8-K
verified 15h ago
“The European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio in adults living with Fabry disease providing a meaningful reduction in treatment burden without compromising efficacy”